Holen Sie sich die Stockscreener-App
3.00
3.54%
-0.11
Handel nachbörslich:
3.02
0.02
+0.67%
Schlusskurs vom Vortag:
$3.11
Offen:
$3.14
24-Stunden-Volumen:
2.06M
Relative Volume:
0.76
Marktkapitalisierung:
$460.74M
Einnahmen:
$38.69M
Nettoeinkommen (Verlust:
$-108.95M
KGV:
-2.454
EPS:
-1.2225
Netto-Cashflow:
$-141.09M
1W Leistung:
+5.63%
1M Leistung:
+15.38%
6M Leistung:
+42.18%
1J Leistung:
+7.14%
1-Tages-Spanne:
$2.97
$3.18
1-Wochen-Bereich:
$2.80
$3.30
52-Wochen-Spanne:
$1.66
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.00 | 451.53M | 38.69M | -108.95M | -141.09M | -1.2225 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
ETFs Investing in Editas Medicine, Inc. Stocks - TradingView
Editas Medicine (NASDAQ:EDIT) Trading 14.4% HigherHere's What Happened - MarketBeat
Ladenburg Thalmann Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $6 - Moomoo
EDIT Initiates Coverage On Ladenburg ThalmannRating Set to Bu - GuruFocus
Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
367,147 Shares in Editas Medicine, Inc. $EDIT Bought by GSA Capital Partners LLP - MarketBeat
EDIT Q2 2026 Earnings: Narrower-than-Expected Loss Underscores Cost DisciplineRevenue Growth Report - vinanet.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Editas Medicine Inc (EDIT) Stock Price, Trades & News - GuruFocus
Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership - Stock Titan
Editas Medicine (EDIT) Institutional Ownership 2026 $EDIT - MarketBeat
Editas Medicine (EDIT) Slides 3.7% as Gene-Editing Stock Tests Key Support at $2.70Collar Trade - Vinanet
Editas Medicine, Inc. (EDIT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Editas Medicine (EDIT) Short Interest & Short Float | Updated Aug 2026 $EDIT - MarketBeat
Editas Medicine (EDIT) Slips to $2.81 as Gene-Editing Stock Nears Critical SupportSchiff Line - dars.gov.et
Editas Medicine, Inc. (EDIT) stock price, news, quote and history - Yahoo Finance Singapore
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Editas Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Weekly Recap: Editas Medicine, Inc. Q2 results and EDIT-401 Australia CTN - TradingView
HC Wainwright Boosts Earnings Estimates for Editas Medicine - MarketBeat
Editas Medicine, Inc. (0IFK.L) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold - MarketBeat
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating - Moomoo
H.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000 - Stock Titan
Editas Medicine, Inc. (EDIT) director reports no share or option holdings - Stock Titan
Editas Medicine, Inc. expected to post a loss of 27 cents a shareEarnings Preview - TradingView
Editas Medicine, Inc. (0IFK.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4 - Moomoo
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus - Yahoo Finance
Editas Medicine Q2 Operating Expenses USD 30. - Moomoo
Editas Medicine (NASDAQ:EDIT) Issues Earnings Results - marketbeat.com
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Editas: Q2 Earnings Snapshot - marketscreener.com
Editas Medicine Q2 net loss narrows and beats estimates - TradingView
Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary - TradingView
Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan - Stock Titan
Editas Medicine Announces Second Quarter 2026 Results and Business Updates - The Manila Times
EDIT: EDIT-401 advances toward clinical trials with robust preclinical data and improved financials - TradingView
Editas Medicine (Nasdaq: EDIT) equity deal lifts cash to $211.6M - Stock Titan
BRIEF-Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million - TradingView
Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates - Moomoo
Editas Medicine earnings beat by $0.12, revenue topped estimates - Investing.com Canada
Editas Medicine appoints Patrick Ellinor to board of directors By Investing.com - Investing.com UK
Editas Medicine appoints Patrick Ellinor to board of directors - Investing.com
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. - The Manila Times
Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Editas Medicine (EDIT) Climbs 4.5% to $2.77 as Support HoldsCollar Trade - vinanet.vn
Renaissance Technologies LLC Raises Position in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine EVP, chief scientific officer, sells $13,157 in stock - Investing.com
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):